Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Debt: 2014-2025

Historic Total Debt for Zevra Therapeutics (ZVRA) over the last 6 years, with Sep 2025 value amounting to $61.3 million.

  • Zevra Therapeutics' Total Debt rose 4.08% to $61.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.3 million, marking a year-over-year increase of 4.08%. This contributed to the annual value of $59.5 million for FY2024, which is 39.14% up from last year.
  • Per Zevra Therapeutics' latest filing, its Total Debt stood at $61.3 million for Q3 2025, which was up 1.02% from $60.7 million recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Total Debt registered a high of $61.3 million during Q3 2025, and its lowest value of $781,000 during Q1 2021.
  • In the last 3 years, Zevra Therapeutics' Total Debt had a median value of $58.3 million in 2024 and averaged $45.8 million.
  • Per our database at Business Quant, Zevra Therapeutics' Total Debt decreased by 0.71% in 2023 and then skyrocketed by 358.95% in 2024.
  • Zevra Therapeutics' Total Debt (Quarterly) stood at $781,000 in 2021, then reached $12.8 million in 2022, then skyrocketed by 234.11% to $42.8 million in 2023, then surged by 39.14% to $59.5 million in 2024, then climbed by 4.08% to $61.3 million in 2025.
  • Its Total Debt stands at $61.3 million for Q3 2025, versus $60.7 million for Q2 2025 and $60.1 million for Q1 2025.